Seeing maltodextrin on a food label does not automatically mean it is worse for your health than table sugar. A short-term blood-sugar measurement and a cellular marker in mice cannot establish an overall human health ranking between the two ingredients.
The distinction becomes concrete in two very different situations: a maltodextrin drink given before heart surgery, and a mouse experiment covering mating, pregnancy and nursing.
Maltodextrin and blood sugar around heart surgery
In a randomized cardiac-surgery trial, 50 adults were assigned either 400 mL of a 12.5% maltodextrin-based carbohydrate drink or 400 mL of water two hours before surgery.
Blood glucose was measured after anesthesia began, immediately after surgery and 24 hours later. At each sampled time, the trial detected no statistically significant difference between the groups.
That result describes blood sugar under those surgical conditions. The measurements did not characterize the immediate glucose peak after drinking. Finding no significant difference at the sampled times therefore does not mean the drink caused no earlier rise in blood sugar.
The short surgical test also cannot establish long-term safety. And because the comparison drink was water, it does not answer whether maltodextrin produces a larger glucose peak than table sugar.
Maltodextrin’s mouse results concern cellular markers
A separate mouse experiment examined exposure during mating, pregnancy and nursing. The maltodextrin group showed increased DNA-damage markers in the brain’s outer layer and in blood cells. The experiment also reported no change in its liver DNA-damage measure.
Those tissue differences matter: the result was not a uniform increase in every organ measured.
Calorie intake increased with maltodextrin exposure too. That limits the ability to separate an effect specific to maltodextrin from an effect involving additional energy intake.
These are laboratory markers from mice. They do not demonstrate disease in people, and they cannot provide an overall human health comparison with table sugar. The results also concern a different outcome from the blood-glucose measurements taken around surgery.
What about diabetes and fatty liver?
The cardiac trial measured blood glucose around an operation. It did not track whether maltodextrin caused new cases of diabetes or fatty-liver disease. The mouse DNA-damage markers do not measure those human outcomes either.
This is why the maltodextrin-versus-sugar question needs a specific outcome attached to it. Blood glucose at a scheduled check, cellular changes in an animal experiment and the development of disease over time are different questions.
Calling maltodextrin the “most dangerous carbohydrate” would turn these narrow outcomes into an overall claim about human health that neither experiment measured.